{"pmid":32347027,"title":"Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports.","text":["Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports.","Since the first case was contracted by coronavirus disease-19 (COVID-19) in Daegu, Korea in February 2020, about 6,800 cases and 130 deaths have been reported on April 9, 2020. Recent studies have reported that patients with diabetes showed higher mortality and they had a worse prognosis than the group without diabetes. In poorly controlled patients with diabetes, acute hyperglycemic crises such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) also might be precipitated by COVID-19. Thus, intensive monitoring and aggressive supportive care should be needed to inadequately controlled patients with diabetes and COVID-19 infection. Here, we report two cases of severe COVID-19 patients with acute hyperglycemic crises in Korea.","Diabetes Metab J","Kim, Na Young","Ha, Eunyeong","Moon, Jun Sung","Lee, Yong Hoon","Choi, Eun Young","32347027"],"abstract":["Since the first case was contracted by coronavirus disease-19 (COVID-19) in Daegu, Korea in February 2020, about 6,800 cases and 130 deaths have been reported on April 9, 2020. Recent studies have reported that patients with diabetes showed higher mortality and they had a worse prognosis than the group without diabetes. In poorly controlled patients with diabetes, acute hyperglycemic crises such as diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) also might be precipitated by COVID-19. Thus, intensive monitoring and aggressive supportive care should be needed to inadequately controlled patients with diabetes and COVID-19 infection. Here, we report two cases of severe COVID-19 patients with acute hyperglycemic crises in Korea."],"journal":"Diabetes Metab J","authors":["Kim, Na Young","Ha, Eunyeong","Moon, Jun Sung","Lee, Yong Hoon","Choi, Eun Young"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347027","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.4093/dmj.2020.0091","keywords":["acidosis","covid-19","diabetes complications","hyperglycemia","ketosis"],"locations":["Daegu","South Korea","South Korea"],"countries":["Korea, Republic of"],"countries_codes":["KOR|Korea, Republic of"],"topics":["Case Report"],"weight":1,"_version_":1665441658257276930,"score":8.599203,"similar":[{"pmid":32220179,"title":"[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","text":["[The Management of Blood Glucose Should be Emphasized in the Treatment of COVID-19].","Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients.","Sichuan Da Xue Xue Bao Yi Xue Ban","Ma, Wan-Xia","Ran, Xing-Wu","32220179"],"abstract":["Based on the higher mortality and the higher proportion of critically ill adults in coronavirus disease 2019 (COVID-19) patients with diabetes, good inpatient glycemic control is particularly important in the comprehensive treatment of COVID-19. Individualized blood glucose target goals and treatment strategies should be made according to specific circumstances of COVID-19 inpatients with diabetes. For mild patients, a strict glycemic control target (fasting plasma glucose (FPG) 4.4-6.1 mmol/L, 2-hour postprandial plasma glucose (2 h PG) 6.1-7.8 mmol/L) are recommended; a target for the glycemic control of common type patients (FPG 6.1-7.8 mmol/L, 2 h PG 7.8-10.0 mmol/L) and subcutaneous insulin deliver therapy are recommended; a target nonfasting blood glucose range of 10.0 mmol or less per liter for severe-type COVID-19 patients, a relatively Less stringent blood glucose control target (FPG 7.8-10.0 mmol/L, 2 h PG 7.8-13.9 mmol/L) for critically ill patients and intravenous insulin infusion therapy are recommended. Due to the rapid changes in the condition of some patients, the risk of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar status (HHS) maybe occur during the treatment. Blood glucose monitoring, dynamic evaluation and timely adjustment of strategies should be strengthened to ensure patient safety and promote early recovery of patients."],"journal":"Sichuan Da Xue Xue Bao Yi Xue Ban","authors":["Ma, Wan-Xia","Ran, Xing-Wu"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32220179","week":"202013|Mar 23 - Mar 29","doi":"10.12182/20200360606","keywords":["blood glucose level","blood glucose monitoring","coronavirus disease 2019, covid-19","diabetes mellitus","inpatient glycemic control","insulin","therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Glucose"],"_version_":1664638743011655680,"score":270.83386},{"pmid":32314455,"title":"COVID-19 infection may cause ketosis and ketoacidosis.","text":["COVID-19 infection may cause ketosis and ketoacidosis.","This study included 658 hospitalized patients with confirmed COVID-19. Forty-two (6.4%) out of 658 patients presented with ketosis on admission with no obvious fever or diarrhea. They had a median age of 47.0 years (IQR, 38.0-70.3), while 16 (38.1%) were men. Patients with ketosis were younger (median age: 47.0 vs 58.0 years, P = 0.003) and had greater prevalence of fatigue (31.0% vs 10.6%, P < 0.001), diabetes (35.7% vs 18.5%, P = 0.007), and digestive disorders (31.0% vs 12.0%, P < 0.001). However, they had longer length of hospital stay (19.0 [12.8-33.3] days vs 16.0 [10.0-24.0] days, P < 0.001) and higher mortality rate (21.4% vs 8.9%, P = 0.017). Three (20.0%) out of the 15 cases with diabetic ketosis developed acidosis, 5 cases (26.7%) with diabetic ketosis died, and one (25.0%) of the deaths presented with acidosis. Two (7.4%) and four (14.3%) cases of the 27 non-diabetic ketotic patients developed severe acidosis and died, respectively, and one (25.0%) of the deaths presented with acidosis. This suggested that COVID-19 infection caused ketosis or ketoacidosis, and induced DKA for those patients with diabetes. Ketosis increased the length of hospital stay and mortality. Meanwhile, diabetes increased the length of hospital stay for patients with ketosis but had no effect on their mortality. This article is protected by copyright. All rights reserved.","Diabetes Obes Metab","Li, Juyi","Wang, Xiufang","Chen, Jian","Zuo, Xiuran","Zhang, Hongmei","Deng, Aiping","32314455"],"abstract":["This study included 658 hospitalized patients with confirmed COVID-19. Forty-two (6.4%) out of 658 patients presented with ketosis on admission with no obvious fever or diarrhea. They had a median age of 47.0 years (IQR, 38.0-70.3), while 16 (38.1%) were men. Patients with ketosis were younger (median age: 47.0 vs 58.0 years, P = 0.003) and had greater prevalence of fatigue (31.0% vs 10.6%, P < 0.001), diabetes (35.7% vs 18.5%, P = 0.007), and digestive disorders (31.0% vs 12.0%, P < 0.001). However, they had longer length of hospital stay (19.0 [12.8-33.3] days vs 16.0 [10.0-24.0] days, P < 0.001) and higher mortality rate (21.4% vs 8.9%, P = 0.017). Three (20.0%) out of the 15 cases with diabetic ketosis developed acidosis, 5 cases (26.7%) with diabetic ketosis died, and one (25.0%) of the deaths presented with acidosis. Two (7.4%) and four (14.3%) cases of the 27 non-diabetic ketotic patients developed severe acidosis and died, respectively, and one (25.0%) of the deaths presented with acidosis. This suggested that COVID-19 infection caused ketosis or ketoacidosis, and induced DKA for those patients with diabetes. Ketosis increased the length of hospital stay and mortality. Meanwhile, diabetes increased the length of hospital stay for patients with ketosis but had no effect on their mortality. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Obes Metab","authors":["Li, Juyi","Wang, Xiufang","Chen, Jian","Zuo, Xiuran","Zhang, Hongmei","Deng, Aiping"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314455","week":"202017|Apr 20 - Apr 26","doi":"10.1111/dom.14057","keywords":["covid-19","dka","infection","ketoacidosis","ketosis"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1664714520208080896,"score":225.62424},{"pmid":32333691,"title":"Managing People with Diabetes Fasting for Ramadan During the COVID-19 Pandemic: A South Asian Health Foundation Update.","text":["Managing People with Diabetes Fasting for Ramadan During the COVID-19 Pandemic: A South Asian Health Foundation Update.","The month of Ramadan forms one of the five pillars of the Muslim faith. Adult Muslims are obligated to keep daily fasts from dawn to sunset, with exceptions. This year Ramadan is due to begin on 23 April 2020 and the longest fast in the UK will be approximately 18 hours in length. In addition, due to the often high-calorie meals eaten to break the fast, Ramadan should be seen as a cycle of fasting and feasting. Ramadan fasting can impact those with diabetes, increasing the risk of hypoglycaemia, hyperglycaemia and dehydration. This year, Ramadan will occur during the global COVID-19 pandemic. Reports show that diabetes appears to be a risk factor for more severe disease with COVID-19. In addition, the UK experience has shown diabetes and COVID-19 is associated with dehydration, starvation ketosis, diabetic ketoacidosis and hyperglycaemic hyperosmolar state. This makes fasting in Ramadan particularly challenging for those Muslims with diabetes. Here, we discuss the implications of fasting in Ramadan during the COVID-19 pandemic and make recommendations for those with diabetes who wish to fast.","Diabet Med","Hanif, S","Ali, S N","Hassanein, M","Khunti, K","Hanif, W","32333691"],"abstract":["The month of Ramadan forms one of the five pillars of the Muslim faith. Adult Muslims are obligated to keep daily fasts from dawn to sunset, with exceptions. This year Ramadan is due to begin on 23 April 2020 and the longest fast in the UK will be approximately 18 hours in length. In addition, due to the often high-calorie meals eaten to break the fast, Ramadan should be seen as a cycle of fasting and feasting. Ramadan fasting can impact those with diabetes, increasing the risk of hypoglycaemia, hyperglycaemia and dehydration. This year, Ramadan will occur during the global COVID-19 pandemic. Reports show that diabetes appears to be a risk factor for more severe disease with COVID-19. In addition, the UK experience has shown diabetes and COVID-19 is associated with dehydration, starvation ketosis, diabetic ketoacidosis and hyperglycaemic hyperosmolar state. This makes fasting in Ramadan particularly challenging for those Muslims with diabetes. Here, we discuss the implications of fasting in Ramadan during the COVID-19 pandemic and make recommendations for those with diabetes who wish to fast."],"journal":"Diabet Med","authors":["Hanif, S","Ali, S N","Hassanein, M","Khunti, K","Hanif, W"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333691","week":"202017|Apr 20 - Apr 26","doi":"10.1111/dme.14312","keywords":["covid-19","diabetes","ramadan","pandemic"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Muslim","Adult Muslims","GBR","GBR","Muslims"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"_version_":1665071049740386304,"score":171.54079},{"pmid":32317205,"title":"Clinical features and multidisciplinary treatment outcome of COVID-19 pneumonia: A report of three cases.","text":["Clinical features and multidisciplinary treatment outcome of COVID-19 pneumonia: A report of three cases.","The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic threatening global public health. In the current paper, we describe our successful treatment of three COVID-19 pneumonia patients cases including severe cases and cases with mortality risk factors. One 32-year-old male COVID-19 patient was diagnosed with severe COVID-19 pneumonia and moderate ARDS. The second COVID-19 pneumonia patient had a history of diabetes and chronic bronchitis. The third case of COVID-19 pneumonia was an 82-year old female patient. All three cases had severe COVID pneumonia and therefore were aggressively managed with a multidisciplinary and personalized therapeutic approach that included nutritional support, antiviral pharmacotherapy, active control of comorbidities, prevention of complication development and psychological intervention. Our experience highlights the importance of the use of a multidisciplinary therapeutic approach that tailors to the specific condition of the patient in achieving a favorable clinical outcome.","J Formos Med Assoc","Liu, Chun","Wu, Changhui","Zheng, Xiangde","Zeng, Fanwei","Liu, Jinping","Wang, Pingxi","Zeng, Fanxin","Yuan, Lin","Zhu, Fangcheng","Gan, Xuemei","Huang, Yucheng","32317205"],"abstract":["The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic threatening global public health. In the current paper, we describe our successful treatment of three COVID-19 pneumonia patients cases including severe cases and cases with mortality risk factors. One 32-year-old male COVID-19 patient was diagnosed with severe COVID-19 pneumonia and moderate ARDS. The second COVID-19 pneumonia patient had a history of diabetes and chronic bronchitis. The third case of COVID-19 pneumonia was an 82-year old female patient. All three cases had severe COVID pneumonia and therefore were aggressively managed with a multidisciplinary and personalized therapeutic approach that included nutritional support, antiviral pharmacotherapy, active control of comorbidities, prevention of complication development and psychological intervention. Our experience highlights the importance of the use of a multidisciplinary therapeutic approach that tailors to the specific condition of the patient in achieving a favorable clinical outcome."],"journal":"J Formos Med Assoc","authors":["Liu, Chun","Wu, Changhui","Zheng, Xiangde","Zeng, Fanwei","Liu, Jinping","Wang, Pingxi","Zeng, Fanxin","Yuan, Lin","Zhu, Fangcheng","Gan, Xuemei","Huang, Yucheng"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317205","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jfma.2020.04.008","keywords":["covid-19","multidisciplinary therapeutic approach","sars-cov-2"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664815087638020096,"score":124.63796},{"pmid":32233013,"title":"Diabetes is a risk factor for the progression and prognosis of COVID-19.","text":["Diabetes is a risk factor for the progression and prognosis of COVID-19.","BACKGOUND: To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID-19). METHODS: A total of 174 consecutive patients confirmed with COVID-19 were studied. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well the treatment measures were collected and analysed. RESULTS: We found that COVID-19 patients without other comorbidities but with diabetes (n = 24) were at higher risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation-related biomarkers such as IL-6, C-reactive protein, serum ferritin and coagulation index, D-dimer, were significantly higher (P < .01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID-19. CONCLUSIONS: Our data support the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. More intensive attention should be paid to patients with diabetes, in case of rapid deterioration.","Diabetes Metab Res Rev","Guo, Weina","Li, Mingyue","Dong, Yalan","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Qin, Renjie","Wang, Haijun","Shen, Yin","Du, Keye","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng","32233013"],"abstract":["BACKGOUND: To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID-19). METHODS: A total of 174 consecutive patients confirmed with COVID-19 were studied. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well the treatment measures were collected and analysed. RESULTS: We found that COVID-19 patients without other comorbidities but with diabetes (n = 24) were at higher risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation-related biomarkers such as IL-6, C-reactive protein, serum ferritin and coagulation index, D-dimer, were significantly higher (P < .01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID-19. CONCLUSIONS: Our data support the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. More intensive attention should be paid to patients with diabetes, in case of rapid deterioration."],"journal":"Diabetes Metab Res Rev","authors":["Guo, Weina","Li, Mingyue","Dong, Yalan","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Qin, Renjie","Wang, Haijun","Shen, Yin","Du, Keye","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233013","week":"202014|Mar 30 - Apr 05","doi":"10.1002/dmrr.3319","keywords":["covid-19","diabetes","prognosis"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664638455285547008,"score":123.15718}]}